Ligelizumab improves angioedema, disease severity and quality-of-life in patients with chronic spontaneous urticaria()

BACKGROUND: Disease burden is particularly high in Chronic Spontaneous Urticaria (CSU) patients with angioedema, and patients whose signs and symptoms are inadequately controlled by H(1)-antihistamines need new treatment options. Here we report an exploratory analysis, from the ligelizumab Phase 2b...

Descripción completa

Detalles Bibliográficos
Autores principales: Metz, Martin, Bernstein, Jonathan A., Giménez-Arnau, Ana M., Hide, Michihiro, Maurer, Marcus, Sitz, Karl, Soong, Weily, Sussman, Gordon, Hua, Eva, Barve, Avantika, Barbier, Nathalie, Balp, Maria-Magdalena, Severin, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: World Allergy Organization 2022
Materias:
Full-Length Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9672946/
https://www.ncbi.nlm.nih.gov/pubmed/36440464
http://dx.doi.org/10.1016/j.waojou.2022.100716

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9672946/
https://www.ncbi.nlm.nih.gov/pubmed/36440464
http://dx.doi.org/10.1016/j.waojou.2022.100716

Ejemplares similares